We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

318 hedge funds and large institutions have $6.84B invested in Abiomed Inc in 2017 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 119 increasing their positions, 105 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 27

52% more call options, than puts

Call options by funds: $29.4M | Put options by funds: $19.3M

19% more capital invested

Capital invested by funds: $5.73B → $6.84B (+$1.1B)

13% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 105

5% more funds holding

Funds holding: 303318 (+15)

17% less funds holding in top 10

Funds holding in top 10: 1210 (-2)

Holders
318
Holders Change
+15
Holders Change %
+4.95%
% of All Funds
7.93%
Holding in Top 10
10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-16.67%
% of All Funds
0.25%
New
48
Increased
119
Reduced
105
Closed
27
Calls
$29.4M
Puts
$19.3M
Net Calls
+$10M
Net Calls Change
-$670K
Name Holding Trade Value Shares
Change
Change in
Stake
ASRS
126
Arizona State Retirement System
Arizona
$4.01M +$998K +6,597 +38%
RHBC
127
R.H. Bluestein & Co
Michigan
$3.98M +$3.14M +20,750 +728%
SCA
128
Snowden Capital Advisors
New York
$3.85M +$14.1K +93 +0.4%
AIM
129
Allen Investment Management
New York
$3.69M +$956K +6,320 +41%
SI
130
Shaker Investments
Ohio
$3.64M +$620K +4,100 +23%
Barclays
131
Barclays
United Kingdom
$3.56M +$183K +1,208 +6%
MSA
132
Mason Street Advisors
Wisconsin
$3.51M +$134K +888 +4%
Jacobs Levy Equity Management
133
Jacobs Levy Equity Management
New Jersey
$3.49M -$1.39M -9,190 -31%
RA
134
Royce & Associates
New York
$3.37M
Handelsbanken Fonder
135
Handelsbanken Fonder
Sweden
$3.37M +$1.81M +12,000 +150%
BA
136
BKS Advisors
Michigan
$3.22M
RJA
137
Raymond James & Associates
Florida
$3.11M +$855K +5,656 +44%
Capital Fund Management (CFM)
138
Capital Fund Management (CFM)
France
$3.06M -$3.81M -25,172 -58%
AAM
139
Advisors Asset Management
Colorado
$3.03M -$508K -3,362 -16%
DBG
140
De Burlo Group
Massachusetts
$2.85M +$2.56M +16,900 New
UONDDL
141
University of Notre Dame du Lac
Indiana
$2.78M -$285K -1,888 -10%
QIM
142
Quantitative Investment Management
Virginia
$2.75M -$5.13M -33,900 -68%
FDCDDQ
143
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.72M
HLA
144
Hamilton Lane Advisors
Pennsylvania
$2.6M +$2.33M +15,414 New
GGHC
145
Gilder Gagnon Howe & Co
New York
$2.54M -$45.2K -299 -2%
OPERF
146
Oregon Public Employees Retirement Fund
Oregon
$2.53M +$60K +397 +3%
Nordea Investment Management
147
Nordea Investment Management
Sweden
$2.45M +$75.9K +502 +4%
LPL Financial
148
LPL Financial
California
$2.37M +$605K +4,000 +41%
BNP Paribas Financial Markets
149
BNP Paribas Financial Markets
France
$2.34M -$350K -2,313 -14%
N
150
Natixis
France
$2.33M +$2.09M +13,805 New

ABMD Hedge Fund Activity: Q3 2017 in Review

318 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q3 2017, worth a combined $6.84B — up 19% from $5.73B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ABMD positions and 27 closed out — a net gain of 21 holders — while 119 added to existing stakes and 105 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $82.2M. The largest seller was Wellington Management Group, cutting an estimated $123M.

  • 318 institutional investors held Abiomed Inc (ABMD) as of Q3 2017, up from 303 in Q2 2017.
  • Funds reported $6.84B of Abiomed Inc stock for Q3 2017, up 19% quarter-over-quarter.
  • 48 funds opened new Abiomed Inc positions in Q3 2017 and 27 closed out, a net change of +21 holders.
  • The largest Abiomed Inc buyer in Q3 2017 was Janus Henderson Group, an estimated $82.2M added.
  • The largest Abiomed Inc seller in Q3 2017 was Wellington Management Group, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2017.